Search for a doctor

Eugene D. Kwon, M.D.

Request an Appointment

Publications

  1. Muniz M, Sartor O, Orme JJ, Koch RM, Rosenow HR, Mahmoud AM, Andrews JR, Kase AM, Riaz IB, Belge Bilgin G, Thorpe MP, Kendi AT, Johnson GB, Ravi P, Kwon ED, Childs DS. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617. J Nucl Med. 2024 Oct 30 [Epub ahead of print]
    View PubMed
  2. Mushtaq A, Mynderse L, Thompson S, Adamo D, Lomas D, Favazza C, Lu A, Kwon E, Woodrum D. Magnetic Resonance Imaging-Guided Cryoablation of Prostate Cancer Lymph Node Metastasis. J Vasc Interv Radiol. 2024 Oct; 35 (10):1474-1480 Epub 2024 June 22
    View PubMed
  3. Belge Bilgin G, Burkett BJ, Bilgin C, Orme JJ, Childs DS, Rincon MM, Abdelrazek AS, Johnson DR, Johnson GB, Kwon ED, Sartor O, Kendi AT. Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. J Nucl Med. 2024 Sep 3; 65 (9):1402-1408 Epub 2024 Sept 03
    View PubMed
  4. Ahmed ME, Mahmoud AM, Reitano G, Zeina W, Lehner K, Day CA, Riaz I, Childs DS, Orme JJ, Tuba Kendi A, Johnson GB, Jeffrey Karnes R, Kwon ED, Andrews JR. Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same? Eur Urol Open Sci. 2024 Aug; 66:38-45 Epub 2024 June 26
    View PubMed
  5. Ahmed ME, Lee MS, Mahmoud AM, Joshi VB, Gopalakrishna A, Bole R, Haloi R, Kendi AT, Bold MS, Bryce AH, Karnes RJ, Kwon ED, Childs DS, Andrews JR. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun; 27 (2):334-338 Epub 2023 Nov 07
    View PubMed
  6. Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Johnson GB, Kendi AT, Kwon ED, Nauseef JT, Morgans AK, Sartor O, Childs DS. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024 Jun; 127:102748 Epub 2024 Apr 30
    View PubMed
  7. Mahmoud AM, Moustafa A, Day C, Ahmed ME, Zeina W, Marzouk UM, Basourakos S, Haloi R, Mahon M, Muniz M, Childs DS, Orme JJ, Riaz IB, Kendi AT, Stish BJ, Davis BJ, Kwon ED, Andrews JR. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies. Cancers (Basel). 2024 May 30; 16 (11)
    View PubMed
  8. Mahmoud AM, Orme JJ, Childs DS, Ahmed ME, Rajkumar A, Kwon ED, Andrews JR. Prostate Cancer and Malignant Ascites: The Mayo Clinic Experience With a Rare and Aggressive Disease Progression. Clin Genitourin Cancer. 2024 Apr; 22 (2):291-294 Epub 2023 Nov 23
    View PubMed
  9. Mahmoud AM, Ahmed ME, Kendi AT, Thorpe M, Johnson GB, Riaz IB, Orme JJ, Kwon ED, Andrews JR, Childs DS. Low PSA radiographic disease progression on C11-choline PET. BJUI Compass. 2024 Mar; 5 (2):319-324 Epub 2023 Oct 25
    View PubMed
  10. Dasari S, McCarthy MR, Wojcik AA, Pitel BA, Samaddar A, Tekin B, Whaley RD, Raghunathan A, Hernandez LH, Jimenez RE, Stish BJ, Thompson RH, Leibovich BC, Boorjian SA, Jeffrey Karnes R, Childs DS, Quevedo JF, Kwon ED, Pagliaro LC, Costello BA, Halling KC, Cheville JC, Kipp BR, Gupta S. Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients. Prostate Cancer Prostatic Dis. 2024 Feb 27. [Epub ahead of print]
    View PubMed
  11. Mahmoud AM, Childs DS, Ahmed ME, Tuba Kendi A, Johnson GB, Orme JJ, Stish BJ, Phillips RM, Park SS, Davis BJ, Andrews JR, Kwon ED. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis. Prostate. 2024 Feb; 84 (3):237-244 Epub 2023 Oct 29
    View PubMed
  12. Joyce DD, Schulte PJ, Kwon ED, Dusetzina SB, Moses KA, Sharma V, Penson DF, Tilburt JC, Boorjian SA. Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment. J Urol. 2023 Aug; 210 (2):290-298 Epub 2023 July 07
    View PubMed
  13. Kemble J, Kwon ED, Karnes RJ. Addressing the need for more therapeutic options in neuroendocrine prostate cancer. Expert Rev Anticancer Ther. 2023 Feb; 23 (2):177-185 Epub 2023 Feb 03
    View PubMed
  14. Andrews JR, Ahmed ME, Sharma V, Britton C, Stish B, Phillips R, Kendi AT, Joshi VB, Sood A, Tollefson MK, Boorjian SA, Karnes RJ, Kwon ED. Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. J Urol. 2022 Dec; 208(6):1240-1249. Epub 2022 Nov 09.
    View PubMed
  15. Alamiri J, Britton CJ, Ahmed ME, Andrews JR, Higa JL, Dundar A, Karnes RJ, Kwon E, Lowe VJ, Kendi AT, Bold MS, Pagliaro LC. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. Prostate. 2022 Dec; 82(16):1483-1490. Epub 2022 Sep 11.
    View PubMed
  16. Joyce DD, Sharma V, Jiang DH, Van Houten HK, Sangaralingham LR, Borah BJ, Kwon ED, Penson DF, Dusetzina SB, Tilburt JC, Boorjian SA. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients. J Urol. 2022 Nov; 208 (5):987-996 Epub 2022 Sept 12
    View PubMed
  17. Jimbo M, Andrews JR, Ahmed ME, Dundar A, Karnes RJ, Bryce AH, Kendi AT, Kwon ED, Lowe VJ, Bold MS. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. Prostate. 2022 Jan; 82(1):41-48. Epub 2021 Oct 11.
    View PubMed
  18. Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in (11)C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Dec 1; 27 (23):6376-6383 Epub 2021 Sept 30
    View PubMed
  19. Ahmed ME, Andrews JR, Joshi VB, Mynderse LA, Tollefson MK, Karnes RJ, Kwon ED. Patient Satisfaction of Telemedicine Visits in an Advanced Prostate Cancer Clinic During the COVID-19 Pandemic. Mayo Clin Proc Innov Qual Outcomes. 2021 Jun; 5 (3):689-692 Epub 2021 May 26
    View PubMed
  20. Boeri L, Sharma V, Kwon E, Stish BJ, Davis BJ, Karnes RJ. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer Prostatic Dis. 2021 Jun; 24 (2):514-523 Epub 2020 Dec 02
    View PubMed
  21. Garg I, Nathan MA, Packard AT, Kwon ED, Larson NB, Lowe V, Davis BJ, Haloi R, Mahon ML, Goenka AH. (11)C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen View PubMed
  22. Deek MP, Taparra K, Dao D, Chan L, Phillips R, Gao RW, Kwon ED, Deville C, Song DY, Greco S, Carducci MA, Eisenberger M, DeWeese TL, Denmeade S, Pienta K, Paller CJ, Antonarakis ES, Olivier KR, Park SS, Stish BJ, Tran PT. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb 1; 109 (2):387-395 Epub 2020 Aug 14
    View PubMed
  23. Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, McHenry MB, Chen A, Logothetis C, CA184-043, Investigators. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. 2020 Dec; 78 (6):822-830 Epub 2020 Aug 15
    View PubMed
  24. Andrews JR, Ahmed ME, Motterle G, Albadri ST, Haloi R, Karnes RJ, Kwon ED, Price KA. A Rare Case of Prostate-Specific Antigen-Producing Metastatic Parotid Adenocarcinoma Developing Androgen Receptor Resistance. Mayo Clin Proc Innov Qual Outcomes. 2020 Oct; 4(5):601-607. Epub 2020 Aug 19.
    View PubMed
  25. Ahmed ME, Andrews JR, Alamiri J, Higa J, Haloi R, Alom M, Motterle G, Joshi V, Shah PH, Jeffrey Karnes R, Kwon E. Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes. Prostate. 2020 Oct; 80 (14):1216-1222 Epub 2020 July 31
    View PubMed
  26. Motterle G, Ahmed ME, Andrews JR, Moschini M, Kwon ED, Karnes RJ. Tumor Seeding after Robot-Assisted Radical Prostatectomy: Literature Review and Experience from a Single Institution. J Urol. 2020 Jun; 203 (6):1141-1146 Epub 2020 Mar 17
    View PubMed
  27. Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH. Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter? Prostate. 2020 Apr; 80 (5):399-406 Epub 2020 Jan 13
    View PubMed
  28. Ahmed ME, Motterle G, Andrews JR, Moschini M, Kwon ED, Karnes RJ. Salvage Radical Prostatectomy After Robot-assisted Laparoscopic Prostatectomy: Case Series. Clin Genitourin Cancer. 2020 Apr; 18 (2):e202-e207 Epub 2019 Oct 16
    View PubMed
  29. Eckel-Passow JE, Ho TH, Serie DJ, Cheville JC, Houston Thompson R, Costello BA, Dong H, Kwon ED, Leibovich BC, Parker AS. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. Cancer Med. 2020 Feb; 9 (3):1152-1160 Epub 2019 Dec 12
    View PubMed
  30. Boeri L, Sharma V, Nehra A, Kwon E, Karnes RJ. The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience. Urol Oncol. 2020 Feb; 38 (2):38.e9-38.e16 Epub 2019 Oct 23
    View PubMed
  31. Jethwa KR, Hellekson CD, Evans JD, Harmsen WS, Wilhite TJ, Whitaker TJ, Park SS, Choo CR, Stish BJ, Olivier KR, Haloi R, Lowe VJ, Welch BT, Quevedo JF, Mynderse LA, Karnes RJ, Kwon ED, Davis BJ. (11)C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities. Adv Radiat Oncol. 2019 Oct-Dec; 4 (4):659-667 Epub 2019 July 04
    View PubMed
  32. Wymer KM, Sharma V, Davis BJ, Kwon ED, Mynderse LA, Karnes RJ. Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence. Clin Genitourin Cancer. 2019 Jun; 17 (3):e536-e540 Epub 2019 Feb 06
    View PubMed
  33. Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ. Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Adv Radiat Oncol. 2019 Apr-Jun; 4 (2):314-322 Epub 2019 Feb 19
    View PubMed
  34. Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Pham T, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H. Corrigendum to "Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy" [Heliyon 4 (12) (December 2018) e01039]. Heliyon. 2019 Mar; 5 (3):e01309 Epub 2019 Mar 18
    View PubMed
  35. Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA. Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. Adv Radiat Oncol. 2019 Jan-Mar; 4 (1):79-89 Epub 2018 Sept 05
    View PubMed
  36. Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Olivier KR, Dong H, Park SS. Prospective Immunophenotyping of CD8(+) T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. Int J Radiat Oncol Biol Phys. 2019 Jan 1; 103 (1):229-240 Epub 2018 Sept 08
    View PubMed
  37. Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Pham T, Orzechowski A, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon. 2018 Dec; 4 (12):e01039 Epub 2018 Dec 18
    View PubMed
  38. Sharma V, Nehra A, Colicchia M, Westerman ME, Kawashima A, Froemming AT, Kwon ED, Mynderse LA, Karnes RJ. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy. Eur Urol. 2018 Jun; 73 (6):879-887 Epub 2017 Nov 28
    View PubMed
  39. Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ. Identification of recurrence sites following post-prostatectomy treatment for prostate cancer using c-11-choline positron emission tomography and multiparametric pelvic magnetic resonance imaging Journal Of Urology. 2018 Mar; 199 (3):726-33
  40. Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using (11)C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. J Urol. 2018 Mar; 199 (3):726-733 Epub 2017 Sept 12
    View PubMed
  41. Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ. Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract Radiat Oncol. 2018 Jan - Feb; 8 (1):28-39 Epub 2017 July 20
    View PubMed
  42. Sharma V, Dong H, Kwon E, Karnes RJ. Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. Eur Urol Focus. 2018 Jan; 4 (1):75-79 Epub 2016 Sept 21
    View PubMed
  43. Bhindi B, Rangel LJ, Mason RJ, Gettman MT, Frank I, Kwon ED, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ. Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. J Urol. 2017 Jul; 198 (1):86-91 Epub 2017 Jan 24
    View PubMed
  44. Erie AJ, Morris JM, Welch BT, Kurup AN, Weisbrod AJ, Atwell TD, Schmit GD, Kwon ED, Callstrom MR. Retrospective Review of Percutaneous Image-Guided Ablation of Oligometastatic Prostate Cancer: A Single-Institution Experience. J Vasc Interv Radiol. 2017 Jul; 28 (7):987-992 Epub 2017 Apr 21
    View PubMed
  45. Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. BMC Urol. 2017 Mar 21; 17 (1):19
    View PubMed
  46. Sonpavde G, Pond GR, Templeton AJ, Kwon ED, De Bono JS. Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2017 Mar; 20 (1):67-71 Epub 2016 Sept 27
    View PubMed
  47. Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED. Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. Eur Urol. 2017 Mar; 71 (3):340-348 Epub 2016 Sept 03
    View PubMed
  48. Moschini M, Morlacco A, Kwon E, Rangel LJ, Karnes RJ. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis. 2017 Mar; 20 (1):117-121 Epub 2017 Jan 03
    View PubMed
  49. Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2017 Mar 1; 97 (3):526-535 Epub 2016 Nov 17
    View PubMed
  50. Sobol I, Zaid HB, Haloi R, Mynderse LA, Froemming AT, Lowe VJ, Davis BJ, Kwon ED, Karnes RJ. Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with (11)C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging. J Urol. 2017 Jan; 197 (1):129-134 Epub 2016 July 20
    View PubMed
  51. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengelov L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol. 2017 Jan; 35 (1):40-47 Epub 2016 Oct 31
    View PubMed
  52. Sobol I, Zaid HB, Haloi R, Mynderse LA, Froemming AT, Lowe VJ, Davis BJ, Kwon ED, Karnes RJ. Contemporary mapping of post-prostatectomy prostate cancer relapse with c-11-choline positron emission tomography and multiparametric magnetic resonance imaging Journal Of Urology. 2017 Jan; 197(1):129-34. Epub 1900 Jan 01.
  53. Zattoni F, Nehra A, Murphy CR, Rangel L, Mynderse L, Lowe V, Kwon E, Karnes RJ. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy. Eur Urol Focus. 2016 Dec; 2 (5):522-531 Epub 2016 Feb 10
    View PubMed
  54. Moser J, Cassivi S, Kwon E, Mansfield AS. PS01.12: C11-Choline Positron Emission Tomography and the Detection of Primary Lung Cancers: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11 (11S):S276 Epub 2016 Oct 28
    View PubMed
  55. McLaren RH, Mynderse LA, Davis BJ, Kwon ED, Lowe VJ, Nathan MA, Karnes R, Parker WP. The Utility of C11 Choline PET/CT in Post-prostatectomy Patients with Biochemical Recurrence: a Comparison to mpMRI. World Jnl of Urol.2016;().
  56. Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Jun 1; 95 (2):696-702 Epub 2016 Jan 29
    View PubMed
  57. Moschini M, Sharma V, Zattoni F, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Kwon ED, Karnes RJ. Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup. J Urol. 2016 Jun; 195 (6):1773-8 Epub 2015 Dec 23
    View PubMed
  58. May EJ, Viers LD, Viers BR, Kawashima A, Kwon ED, Karnes RJ, Froemming AT. Prostate cancer post-treatment follow-up and recurrence evaluation. Abdom Radiol (NY). 2016 May; 41 (5):862-76
    View PubMed
  59. Moschini M, Briganti A, Murphy CR, Bianchi M, Gandaglia G, Montorsi F, Quevedo JF, Carlson R, Kwon E, Karnes RJ. Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. Eur Urol. 2016 Feb; 69 (2):193-6 Epub 2015 Aug 08
    View PubMed
  60. Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E, Karnes RJ. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy. Eur Urol. 2016 Jan; 69 (1):135-42 Epub 2015 Apr 10
    View PubMed
  61. Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J, Kwon E, Leibovich B. The Estrogen Pathway: Estrogen Receptor-alpha, Progesterone Receptor, and Estrogen Receptor-beta Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. Clin Genitourin Cancer. 2015 Oct; 13 (5):476-84 Epub 2015 Apr 15
    View PubMed
  62. Gustafson MP, Lin Y, Bleeker JS, Warad D, Tollefson MK, Crispen PL, Bulur PA, Harrington SM, Laborde RR, Gastineau DA, Leibovich BC, Cheville JC, Kwon ED, Dietz AB. Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2015 Sep 15; 21 (18):4224-33 Epub 2015 May 21
    View PubMed
  63. Sobol I, Thompson RH, Dong H, Krco C, Kwon ED. Immunotherapy in prostate cancer. Curr Urol Rep. 2015 Jun; 16 (6):34
    View PubMed
  64. Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res. 2015 Jun; 3 (6):610-9 Epub 2015 Feb 19
    View PubMed
  65. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 1; 21 (3):561-8 Epub 2014 Nov 25
    View PubMed
  66. Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ, Mynderse LA, Kwon ED. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol. 2015 Jan; 193 (1):111-6 Epub 2014 Aug 20
    View PubMed
  67. Gibbons RM, Liu X, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. Cancer Immunol Immunother. 2014 Aug; 63(8):859-67. Epub 2014 Jun 04.
    View PubMed
  68. Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014 Jul; 9 (7):1036-1040
    View PubMed
  69. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun; 15 (7):700-12 Epub 2014 May 13
    View PubMed
  70. Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model. Mayo Clin Proc. 2014 Mar; 89 (3):308-18 Epub 2014 Jan 31
    View PubMed
  71. Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Kufer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, Shariat SF. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014 Jan; 40 (1):121-7 Epub 2013 Sept 18
    View PubMed
  72. Joseph RW, Parasramka M, Eckel-Passow JE, Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Huu Ho T, Castle EP, Cheville J, Kwon ED, Thompson EA, Parker A. Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. Cancer Immunol Res. 2013 Dec; 1 (6):378-85 Epub 2013 Aug 29
    View PubMed
  73. Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int. 2013 Jun; 111 (7):1046-53 Epub 2013 Apr 02
    View PubMed
  74. Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, Dong H. Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology. 2013 Jun 1; 2 (6):e23972 Epub 2013 June 06
    View PubMed
  75. Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013 Apr; 189 (4):1308-13 Epub 2012 Oct 30
    View PubMed
  76. Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, Aubry MC. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer. 2013 Mar; 14 (2):157-63 Epub 2012 Aug 04
    View PubMed
  77. Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH, Oosterwijk E. Potential role of genetic markers in the management of kidney cancer. Eur Urol. 2013 Feb; 63(2):333-40. Epub 2012 Sep 24.
    View PubMed
  78. Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC, Bauer PR, Abraham RS, Tollefson MK, Kwon ED, Gastineau DA, Dietz AB. Immune monitoring using the predictive power of immune profiles. J Immunother Cancer. 2013; 1:7. Epub 2013 Jun 27.
    View PubMed
  79. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Frontiers in Oncology. 2013; 2 JAN:215.
  80. Gibbons RM, Liu X, Pulko V, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology. 2012 Oct 1; 1 (7):1061-1073
    View PubMed
  81. Frigola X, Inman BA, Krco CJ, Liu X, Harrington SM, Bulur PA, Dietz AB, Dong H, Kwon ED. Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol Lett 2012 Feb 29; 142 (1-2):78-82 Epub 2011 Nov 25
    View PubMed
  82. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012; 2:215. Epub 2013 Jan 22.
    View PubMed
  83. Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-h1 expressed by activated CD8 T cells is essential for their survival. J Immunol. 2011 Dec 1; 187 (11):5606-14 Epub 2011 Oct 24
    View PubMed
  84. Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011 Apr 1; 17 (7):1915-23 Epub 2011 Feb 25
    View PubMed
  85. Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1343-9. Epub 2010 Jul 02.
    View PubMed
  86. Wada DA, Wilcox RA, Harrington SM, Kwon ED, Ansell SM, Comfere NI. Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sezary syndrome. Am J Hematol. 2011 Mar; 86(3):325-7. Epub 2011 Feb 15.
    View PubMed
  87. Archibald DJ, Neff BA, Voss SG, Splinter PL, Driscoll CL, Link MJ, Dong H, Kwon ED. B7-H1 expression in vestibular schwannomas. Otol Neurotol. 2010 Aug; 31 (6):991-7
    View PubMed
  88. Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED. Tissue microarrays: one size does not fit all. Diagn Pathol. 2010 Jul 7; 5:48 Epub 2010 July 07
    View PubMed
  89. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Leibovich BC, Kwon ED. T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Urology. 2009 Dec; 74 (6):1359-64 Epub 2009 June 07
    View PubMed
  90. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol. 2009 Sep 15; 183 (6):3634-41 Epub 2009 Aug 26
    View PubMed
  91. Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, Witzig TE, Ansell SM. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009 Sep 3; 114 (10):2149-58 Epub 2009 July 13
    View PubMed
  92. Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009 May 15; 115 (10):2092-103
    View PubMed
  93. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009 Mar 15; 15 (6):2174-80 Epub 2009 Mar 10
    View PubMed
  94. Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy. 2009 Jan; 1(1):129-39.
    View PubMed
  95. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Urol. 2008 Oct; 180(4 Part 1):1302.
  96. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008 Oct 1; 113 (7):1544-51
    View PubMed
  97. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Kwon ED, Leibovich BC. Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation. Urology. 2008 Oct; 72 (4):927-32 Epub 2008 Mar 28
    View PubMed
  98. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008 Aug 15; 14 (16):5150-7 Epub 2008 Aug 11
    View PubMed
  99. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008 Aug 1; 68 (15):6054-8
    View PubMed
  100. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008 Aug 1; 113 (3):450-60
    View PubMed
  101. Parker AS, Lohse CM, Leibovich BC, Cheville JC, Sheinin YM, Kwon ED. Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. Hum Pathol. 2008 Aug; 39 (8):1176-84 Epub 2008 June 05
    View PubMed
  102. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED, Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008 Aug 1; 14 (15):4800-8
    View PubMed
  103. Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL, Kwon ED. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 2008 Jun 15; 112 (12):2676-82
    View PubMed
  104. Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63.
    View PubMed
  105. Routh JC, Ashley RA, Sebo TJ, Lohse CM, Husmann DA, Kramer SA, Kwon ED. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol. 2008 May; 179 (5):1954-9; discussion 1959-60 Epub 2008 Mar 20
    View PubMed
  106. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008 Apr 1; 112 (7):1471-9
    View PubMed
  107. Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC, Kwon ED. Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. J Immunol. 2008 Mar 1; 180 (5):3578-84
    View PubMed
  108. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008 Feb; 179 (2):468-71; discussion 472-3
    View PubMed
  109. Magera JS Jr, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, Blute ML. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology. 2008 Feb; 71 (2):278-82
    View PubMed
  110. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007 Oct 20; 25 (30):4757-64
    View PubMed
  111. Tollefson MK, Thompson RH, Sheinin Y, Lohse CM, Cheville JC, Leibovich BC, Kwon ED. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007 Aug 15; 110 (4):783-90
    View PubMed
  112. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007 Aug 15; 67 (16):7893-900 Epub 2007 Aug 08
    View PubMed
  113. Thompson RH, Blute ML, Krambeck AE, Lohse CM, Magera JS, Leibovich BC, Kwon ED, Frank I, Cheville JC. Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. Am J Surg Pathol. 2007 Jul; 31 (7):1089-93
    View PubMed
  114. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007 Apr 15; 109 (8):1499-505
    View PubMed
  115. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007 Apr 1; 13 (7):2075-81
    View PubMed
  116. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13 (6):1749-56
    View PubMed
  117. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13 (6):1757-61
    View PubMed
  118. Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets. 2007 Feb; 7 (1):15-30
    View PubMed
  119. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s.
    View PubMed
  120. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007 Jan 15; 13 (2 Pt 2):709s-715s
    View PubMed
  121. Mercader M, Sengupta S, Bodner BK, Manecke RG, Cosar EF, Moser MT, Ballman KV, Wojcik EM, Kwon ED. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int. 2007 Jan; 99(1):60-7.
    View PubMed
  122. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer. 2006 Dec; 5 (3):206-11
    View PubMed
  123. Blocki FA, Radhakrishnan S, Van Keulen VP, Heckman KL, Ciric B, Howe CL, Rodriguez M, Kwon E, Pease LR. Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC. FASEB J. 2006 Nov; 20 (13):2408-10 Epub 2006 Oct 03
    View PubMed
  124. Krambeck AE, Leibovich BC, Lohse CM, Kwon ED, Zincke H, Blute ML. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol. 2006 Nov; 176 (5):1990-5; discussion 1995
    View PubMed
  125. Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC. Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol. 2006 Nov; 176 (5):1978-82; discussion 1982-3
    View PubMed
  126. Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol. 2006 Sep-Oct; 24 (5):442-7
    View PubMed
  127. Inman BA, DiMarco DS, Slezak JM, Sebo TJ, Kwon ED, Leibovich BC, Blute ML, Zincke H. Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology. 2006 Sep; 68(3):604-8. Epub 2006 Sep 18.
    View PubMed
  128. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Zincke H, Blute ML. Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol. 2006 Sep; 176 (3):900-3; discussion 903-4
    View PubMed
  129. Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006 Aug 15; 107(4):712-20.
    View PubMed
  130. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006 Jul 5; 103 (27):10391-10396 Epub 2006 June 23
    View PubMed
  131. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006 Jul 1; 107 (1):37-45
    View PubMed
  132. Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, Cheville JC, Kwon ED. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 2006 Jul 1; 107 (1):46-53
    View PubMed
  133. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006 Apr 1; 66 (7):3381-5
    View PubMed
  134. Sengupta S, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML, Kwon ED. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer. 2006 Jan 15; 106 (2):304-12
    View PubMed
  135. Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr Pharm Des. 2006; 12: (7)807-17.
    View PubMed
  136. Sengupta S, Cheville JC, Corless CL, Lohse CM, Heinrich MC, Kwon ED, Zincke H, Blute ML, Leibovich BC. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol. 2006 Jan; 175 (1):53-6
    View PubMed
  137. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005 Nov 15; 104 (10):2084-91
    View PubMed
  138. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: Biology, therapeutics, and challenges. J Clin Oncol. 2005 Nov 10; 23(32):8262-9.
    View PubMed
  139. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005 Nov; 174 (5):1759-63; discussion 1763
    View PubMed
  140. Thompson RH, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, Kuntz SM, Sengupta S, Kwon ED, Blute ML. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology. 2005 Nov; 66 (5 Suppl):10-4
    View PubMed
  141. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol. 2005 Oct; 174 (4 Pt 1):1218-21
    View PubMed
  142. Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005 Aug 1; 104 (3):511-20
    View PubMed
  143. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005 Jul 1; 104 (1):53-60
    View PubMed
  144. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005 Jun; 173 (6):1893-6
    View PubMed
  145. Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, Zincke H, Blute ML. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005 Mar; 173 (3):918-21
    View PubMed
  146. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Kwon ED, Frank I, Thompson RH, Blute ML. Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol. 2005 Mar; 173 (3):716-9
    View PubMed
  147. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Kwon ED, Zincke H. pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol. 2005 Feb; 173 (2):380-4
    View PubMed
  148. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED. Aberrant expression of costimulatory B7-H1 in clear cell renal cell carcinoma. The American Journal of Urology Review. 2005; 3(5):244-9.
  149. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004 Dec 7; 101 (49):17174-9 Epub 2004 Nov 29
    View PubMed
  150. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004 Nov 15; 173 (10):6098-108
    View PubMed
  151. Mulhall JP, Martin DJ, Lubrano T, Moser M, Kwon E, Wojcik E, Shankey TV. Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int J Impot Res. 2004 Apr; 16(2):99-104.
    View PubMed
  152. Krejci KG, Markiewicz MA, Kwon ED. Immunotherapy for urological malignancies. J Urol. 2004 Feb; 171 (2 Pt 1):870-6
    View PubMed
  153. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 Apr 1; 97 (7):1663-71
    View PubMed
  154. Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer - Advances in immunotherapy. Biodrugs. 2003; 17(2):131-8.
    View PubMed
  155. Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, Kwon E, Greenberg NM, Lee C. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res. 2002 Dec 15; 62(24):7135-8.
    View PubMed
  156. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001 Dec 4; 98(25):14565-70.
    View PubMed
  157. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res. 2001 Aug 1; 61(15):5857-60.
    View PubMed
  158. Ellis TM, Moser MT, Le PT, Flanigan RC, Kwon ED. Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol. 2001 Apr; 13(4):553-8.
    View PubMed
  159. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol. 2000 Oct; 12(5):589-96.
    View PubMed
  160. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000 May; 6(5):1755-66.
    View PubMed
  161. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000 May 1; 60(9):2444-8.
    View PubMed
  162. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A. 1999 Dec 21; 96(26):15074-9.
    View PubMed
  163. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997 Aug 15; 57(16):3325-30.
    View PubMed
  164. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul 22; 94(15):8099-103.
    View PubMed
  165. Burg MB, Kwon ED, Kultz D. Regulation of gene expression by hypertonicity. Annu Rev Physiol. 1997; 59:437-55.
    View PubMed
  166. Burg MB, Kwon ED, Peters EM. Glycerophosphocholine and betaine counteract the effect of urea on pyruvate kinase. Kidney Int Suppl. 1996 Dec; 57:S100-4.
    View PubMed
  167. Burg MB, Kwon ED, Kultz D. Osmotic regulation of gene expression. FASEB J. 1996 Dec; 10(14):1598-606.
    View PubMed
  168. Cooper CS, Kwon ED, Donovan JF Jr. Traumatic ureteroduodenal fistula. Journal of Trauma-Injury Infection & Critical Care. 1996 Sep; 41(3):553-5.
    View PubMed
  169. Kwon ED, Dooley JA, Jung KY, Andrews PM, Garcia-Perez A, Burg MB. Organic osmolyte distribution and levels in the mammalian urinary bladder in diuresis and antidiuresis. Am J Physiol. 1996 Jul; 271(1 Pt 2):F230-3.
    View PubMed
  170. Kwon ED, Donovan JF, Schedl HP. Physical determinants of solute and water clearance by the perfused dog jejunum. J Surg Res. 1996 Feb 15; 61(1):215-20.
    View PubMed
  171. Donovan JF Jr, Hade DK, Lavelle JP, Kwon ED. Continent small-intestine reservoir construction: a tapered intussusceptum promotes sustained continence. World J Urol. 1996; 14(6):370-4.
    View PubMed
  172. Kwon ED, Zablocki K, Peters EM, Jung KY, Garcia-Perez A, Burg MB. Betaine and inositol reduce MDCK cell glycerophosphocholine by stimulating its degradation. Am J Physiol. 1996 Jan; 270(1 Pt 1):C200-7.
    View PubMed
  173. Kwon ED, Zablocki K, Jung KY, Peters EM, Garcia-Perez A, Burg MB. Osmoregulation of GPC:choline phosphodiesterase in MDCK cells: different effects of urea and NaCl. Am J Physiol. 1995 Jul; 269(1 Pt 1):C35-41.
    View PubMed
  174. Kwon ED, Jung KY, Edsall LC, Kim HY, Garcia-Perez A, Burg MB. Osmotic regulation of synthesis of glycerophosphocholine from phosphatidylcholine in MDCK cells. Am J Physiol. 1995 Feb; 268(2 Pt 1):C402-12.
    View PubMed
  175. Kwon ED, Schedl HP, Donovan JF Jr. Deoxycholate effects on plasma solute clearance by gut perfusion in dog. J Surg Res. 1994 Nov; 57(5):549-55.
    View PubMed
  176. Hade DK, Donovan JF Jr, Kwon ED, Stokes JB, Bertholf MB, Flanigan MJ, Schedl HP. The use of rhein to augment fluid and electrolyte secretion in the continent jejunal reservoir. Surg Forum. 1994; XLV:791-4.
  177. Kwon ED, Schedl HP, Donovan JF, Carson RA, Williams RD. Transport properties of an in situ jejunal reservoir in dogs. Am J Physiol. 1992 Mar; 262(3 Pt 2):F517-22.
    View PubMed
  178. Kwon ED, Loening SA, Hawtrey CE. Radical prostatectomy and adjuvant radioactive gold seed placement: results of treatment at 5 and 10 years for clinical stages A2, B1 and B2 cancer of the prostate. J Urol. 1991 Mar; 145(3):524-31.
    View PubMed
  179. Kwon ED, Donovan JF, Schedl HP, Williams RD. Replacement of lost renal function: Solute and coupled urea nitrogen and hydrogen ion excretion in the jejunal reservoir/urease system. Surgical Form. 1991;XLII.
  180. Loening SA, Kwon ED. Percutaneous transperineal placement of radioactive gold seed for treatment of localized prostatic carcinoma. J Endourol. 1989;3(2):201-8.
  181. Kwon ED, Williams RD. Magnetic resonance imaging in the evaluation of prostate cancer. World J Urol. 1989; 7:17-21.
PST-20222543